{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-058223","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.204896+00:00","generated_at":"2026-06-25T21:39:50.444380+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TELA Bio Q1 revenue $8.2M (+40% YoY); net loss widens to $10.9M","bullets":["Revenue grew 40% YoY to $8.2M; OviTex PRS revenue up 111% YoY.","Gross margin improved to 61% from 59% on lower excess/obsolete inventory adjustments.","Net loss $10.9M vs $8.1M; operating loss $9.8M vs $7.3M.","Cash and equivalents $33.0M; FY2022 revenue guidance reaffirmed at $40-45M.","Appointed D. Taylor Ocasio as General Counsel."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-058223","json":"https://secwatch.observer/filing/0001104659-22-058223.json","markdown":"https://secwatch.observer/filing/0001104659-22-058223.md","text":"https://secwatch.observer/filing/0001104659-22-058223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922058223/0001104659-22-058223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922058223/tm2215020d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:39:50.444380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}